Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORELINE: Zuranolone 1-Year Safety and Re-Treatment Study in MDD
NCT03864614Phase 3Completed
- Sponsor
- Biogen
- Start
- Feb 2019
- Primary completion
- Jun 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zuranolone in major depressive disorder (MDD), sponsored by Biogen. Primary endpoints: Treatment Emergent Adverse Events at 52 weeks and Suicidal Ideation or Suicidal Behavior at 52 weeks. Started Feb 2019; status: completed.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03864614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864614.